We also assess the rationale for clinical trials of IL-1 inhibitors aimed at preserving β-cell functional mass in patients with new-onset T1DM.

most commonly drugs that target the interleukin-1 (IL-1) pathway including anakinra (Kineret) and canakinumab (Ilaris) -- unlike in other forms of inflammatory arthritis in which tumor necrosis factor ...

and IL-1. 1 Early-generation p38 inhibitors (for example, BIRB796 and SCIO469) showed only moderate success owing to their poor specificity and dose-dependent toxicity. More recently, new ...